Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

This was the stock's second consecutive day of losses.

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Stocks are marking daily gains, but it's nothing to write home about as investors await an update on tariffs while readying ...

NRG Energy Inc. closed 8.84% short of its 52-week high of $115.38, which the company achieved on January 22nd.

Long-term investments will likely pull it out of its slump as 12-month stock performance underperforms.

Life sciences group Repligen (RGEN) is set for healthy revenue growth, boosted by its “underappreciated” AI capabilities.Maximize Your ...

Wells Fargo analyst Brandon Couillard maintained a Buy rating on Repligen (RGEN – Research Report) today and set a price target of $180.00. The ...

TD Cowen has started coverage of Repligen (NASDAQ:RGEN) with a buy rating, citing the company's limited exposure to NIH funding cuts and China. The investment bank said Repligen (NASDAQ:RGEN) was ...

TD Cowen initiated coverage of Repligen (RGEN) with a Buy rating and $200 price target Repligen is well positioned for “industry-leading” ...

TD Cowen began coverage on Repligen Corporation (NASDAQ:RGEN), a prominent bioprocessing company, with a Buy rating and a price target set at $200. The firm highlighted Repligen's strong position for ...